BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 20451283)

  • 21. Comparison of staging systems to predict survival in hepatocellular carcinoma.
    Pascual S; Zapater P; Such J; García-Herola A; Sempere L; Irurzun J; Palazón JM; Carnicer F; Pérez-Mateo M
    Liver Int; 2006 Aug; 26(6):673-9. PubMed ID: 16842323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of survival of patients with hepatocellular carcinoma predicted by different staging systems using multivariate analysis.
    Nanashima A; Omagari K; Tobinaga S; Shibata K; Sumida Y; Mine M; Morino S; Shibasaki S; Ide N; Shindou H; Nagayasu T
    Eur J Surg Oncol; 2005 Oct; 31(8):882-90. PubMed ID: 15993031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma.
    Seo YS; Kim YJ; Um SH; Yoo H; Lee JW; Kim YS; Jeen YT; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1267-75. PubMed ID: 18637054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.
    Kudo M; Chung H; Haji S; Osaki Y; Oka H; Seki T; Kasugai H; Sasaki Y; Matsunaga T
    Hepatology; 2004 Dec; 40(6):1396-405. PubMed ID: 15565571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey.
    Kitai S; Kudo M; Izumi N; Kaneko S; Ku Y; Kokudo N; Sakamoto M; Takayama T; Nakashima O; Kadoya M; Matsuyama Y; Matsunaga T
    Dig Dis; 2014; 32(6):717-24. PubMed ID: 25376289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Lin HC; Huang YH; Wu JC; Chiang JH; Lee PC; Lee SD
    Cancer; 2006 Jul; 107(1):141-8. PubMed ID: 16708358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular carcinoma in uremic patients: is there evidence for an increased risk of mortality?
    Lee YH; Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Huo TI
    J Gastroenterol Hepatol; 2013 Feb; 28(2):348-56. PubMed ID: 23190248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP.
    Baek YH; Lee JH; Jang JS; Lee SW; Han JY; Jeong JS; Choi JC; Kim HY; Han SY
    Hepatogastroenterology; 2009; 56(91-92):763-7. PubMed ID: 19621698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective validation of the Barcelona Clinic Liver Cancer staging system.
    Cillo U; Vitale A; Grigoletto F; Farinati F; Brolese A; Zanus G; Neri D; Boccagni P; Srsen N; D'Amico F; Ciarleglio FA; Bridda A; D'Amico DF
    J Hepatol; 2006 Apr; 44(4):723-31. PubMed ID: 16488051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system.
    Farinati F; Rinaldi M; Gianni S; Naccarato R
    Cancer; 2000 Dec; 89(11):2266-73. PubMed ID: 11147597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems.
    Huo TI; Hsia CY; Huang YH; Lin HC; Lee PC; Lui WY; Chiang JH; Chiou YY; Loong CC; Lee SD
    J Clin Gastroenterol; 2009 Sep; 43(8):773-81. PubMed ID: 19262404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials.
    Li X; Dong M; Lin Q; Chen ZH; Ma XK; Xing YF; Wan XB; Wen JY; Wei L; Chen J; Wu XY
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):86-92. PubMed ID: 23279888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score.
    Kitai S; Kudo M; Minami Y; Ueshima K; Chung H; Hagiwara S; Inoue T; Ishikawa E; Takahashi S; Asakuma Y; Haji S; Osaki Y; Oka H; Seki T; Kasugai H; Sasaki Y; Matsunaga T
    Intervirology; 2008; 51 Suppl 1():86-94. PubMed ID: 18544953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Lee YH; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiou YY; Huo TI; Lee SD
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1581-8. PubMed ID: 22497632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy.
    Seong J; Shim SJ; Lee IJ; Han KH; Chon CY; Ahn SH
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1037-42. PubMed ID: 17234356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of the CLIP scoring system for prediction of postoperative prognosis of patients with large hepatocellular carcinoma.
    Noda T; Sasaki Y; Yamada T; Eguchi H; Yano M; Ohigashi H; Ishikawa O; Imaoka S
    J Hepatobiliary Pancreat Surg; 2009; 16(4):538-45. PubMed ID: 19367360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
    World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients.
    Lee YH; Hsu CY; Hsia CY; Huang YH; Su CW; Lin HC; Chiou YY; Huo TI
    Aliment Pharmacol Ther; 2012 Sep; 36(6):551-9. PubMed ID: 22817677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients.
    Liu PH; Hsu CY; Hsia CY; Lee YH; Huang YH; Su CW; Lee FY; Lin HC; Huo TI
    Eur J Cancer; 2016 Aug; 63():25-33. PubMed ID: 27259100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.